ArticleTheranostics2020

The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.

Renaud Grépin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.